Mylan and Biocon Launch Semglee (insulin glargine injection) as Vials and Pre-Filled Pen in the US

 Mylan and Biocon Launch Semglee (insulin glargine injection) as Vials and Pre-Filled Pen in the US

Mylan and Biocon Launch Semglee (insulin glargine injection) as Vials and Pre-Filled Pen in the US

Shots:

  • The companies have launched Semglee (insulin glargine injection) in a vial and pre-filled pen at WAC of $147.98/ package of (5) 3ml pens and $98.65/ 10ml vial, representing the lowest WAC for any long-acting insulin glargine
  • The US FDA has approved Semglee for the same indications as to its reference product Sanofi’s Lantus, thus expanding access for millions of patients living with diabetes
  • Additionally, Mylan has submitted all necessary documentation to the FDA, requesting the approval of Semglee as a biosimilar to Lantus under the 351(k) pathway. Semglee has received regulatory approval in 45+ countries and is the third FDA’s approved product under the Mylan-Biocon collaboration

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Diet Doctor

Related News: Mylan and Biocon Receive the US FDA’s Approval for Semglee (biosimilar, insulin glargine)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post